regulators have been cooperative in bringing capacity back up to speed. The CEO acknowledged the unique situation of the pandemic and said U.S. The manufacturing cutoff also delayed the start of a few clinical trials for new indications of the drug, Walbert said. 24 earnings call, Walbert said the growth would have been even greater without the supply disruption. The full-year sales of $820 million were more than 20 times more than what the company forecast in a Feb. Tepezza brought in $344 million in sales for Horizon in the fourth quarter of 2020. seeks to vaccinate every adult in the country by the end of May following a slow initial rollout. The disruption has continued into March 2021 as the U.S. government invoked the Defense Production Act of 1950 to make Moderna Inc.'s COVID-19 vaccine at Horizon's third-party manufacturing facility run by contractor Catalent Inc. "That was one of the critical aspects, not only the efficacy of the drug but the fact that we found alternative sites of care versus hospitals so that these patients can get treated in the face of the pandemic made a huge difference," the CEO said.Īnd then in December another more acute effect of the pandemic disrupted supply of Tepezza completely: As part of Operation Warp Speed, the U.S. "What we learned immediately with the pandemic was that these patients could not go get treated at the hospital."Īt varying times during the year, 95% to almost all infusions were performed at alternative sites, which Horizon had to bring online quickly, Walbert said. "One of the key things that we learned and that we had to adapt to immediately, was that we expected reimbursement and most of the infusions to be held in the hospital setting," the CEO said. Tepezza is an infused medicine that is given to patients in a healthcare setting at a time when many hospitals were focusing on treating those infected with COVID-19. To get to that point so soon after entering the market, Horizon had to pivot strategically as the pandemic became more severe at the outset, Walbert said. In Tepezza's first year on the market, the thyroid eye disease treatment approached blockbuster status with $820 million in 2020 sales, contributing to what Walbert, who is also Horizon's c hairman and president, called "one of the most successful rare disease drug launches ever" in an interview with S&P Global Market Intelligence. Horizon Therapeutics CEO Tim Walbert Source: Horizon Therapeutics and Wyeth.A little more than a year from Horizon Therapeutics PLC's launch of rare eye disease drug Tepezza, CEO Tim Walbert is looking back at the ways the company has had to navigate a successful drug launch in trying times stemming from the COVID-19 pandemic. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. From 1998 to 2001, Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. From 2001 to 2005, he served as divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. Before IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. Before joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Tim Walbert joined Horizon in June 2008 as president and chief executive officer and has served as chairman of the company’s board of directors since 2010. Horizon Therapeutics - Pharmaceuticals Profile
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |